Skip Navigation

Cardiovascular Research 1997 35(3):422-430; doi:10.1016/S0008-6363(97)00162-4
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bowles, N. E.
Right arrow Articles by Towbin, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowles, N. E.
Right arrow Articles by Towbin, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Prospects for adenovirus-mediated gene therapy of inherited diseases of the myocardium

Neil E. Bowlesa, Qing Wanga and Jeffrey A. Towbina,b,*

aDepartment of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
bDepartment of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

* Corresponding author. Pediatric Cardiology, Baylor College of Medicine, One Baylor Plaza, Room 333E, Houston TX 77030, USA. Tel.: +1 713 7987342; Fax: +1 713 7988085; E-mail: jtowbin@bcm.tmc.edu

Received 10 February 1997; accepted 5 June 1997

KEYWORDS Adenovirus; Cardiomyopathy; Long QT

The first 150 words of the full text of this article appear below.


   1 Introduction
 
Many genetic loci linked to a variety of diseases have been identified, and disease-causing mutations characterized. These have included diseases of the myocardium, such as X-linked dilated cardiomyopathy [1–3], hypertrophic cardiomyopathy [4–6], and Long QT syndrome [7–9]. The elucidation of gene defects has allowed different therapeutic strategies to be proposed, including the use of pharmaceutical agents to replace or to antagonize the mutated protein, and replacement of the defective gene with a functional one (gene therapy). There have been many publications describing the use of vectors to transduce target cells for the correction of gene defects or for anti-viral therapy (for reviews see [10–14]). Such vectors have included recombinant retroviruses, adenoviruses, adeno-associated viruses, and herpes viruses, as well as non-viral vectors. Each vector has inherent advantages and disadvantages. At this time the adenoviruses are most commonly used and represent the most likely vector for efficient transduction . . . [Full Text of this Article]


   2 Recombinant adenoviruses as gene therapy vectors
 

   3 Dilated cardiomyopathy
 

   4 Hypertrophic cardiomyopathy
 

   5 Long QT syndrome
 

   6 Adenovirus-mediated cardiac disease
 

   7 Summary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens
Gene therapy in the cardiovascular system: an update
Cardiovasc Res, December 1, 1999; 44(3): 498 - 506.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Lusky, L. Grave, A. Dieterle, D. Dreyer, M. Christ, C. Ziller, P. Furstenberger, J. Kintz, D. Ali Hadji, A. Pavirani, et al.
Regulation of Adenovirus-Mediated Transgene Expression by the Viral E4 Gene Products: Requirement for E4 ORF3
J. Virol., October 1, 1999; 73(10): 8308 - 8319.
[Abstract] [Full Text] [PDF]